AOD 9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, often referred to as hGH fragment 176-191. It was originally investigated for its potential role in fat metabolism and weight-management research.
Unlike full growth hormone, AOD 9604 was designed to focus on the fat-metabolism-related portion of the growth hormone molecule without producing the broader growth-promoting or blood-sugar-related effects associated with full hGH.
Human research has shown AOD 9604 to be generally well tolerated, but weight-loss results have been mixed, with early signals not consistently confirmed in later trials.
AOD 9604 At A Glance
| Category | Details |
|---|---|
| Compound Type | Synthetic hGH fragment peptide |
| Common Name | AOD 9604 |
| Related Name | hGH Fragment 176-191 |
| Primary Research Interest | Fat metabolism, lipolysis, metabolic research |
| Typical Route Discussed | Subcutaneous injection |
| Common Research Frequency | Once daily |
| Common Timing | Morning, fasted, or before activity |
| Half-Life | Short, often discussed as requiring daily use |
| Research Status | Investigational, not approved as a therapeutic drug |
| Athlete Note | Prohibited by WADA |
How AOD 9604 Works
AOD 9604 is based on a small region of the growth hormone molecule believed to be involved in lipid metabolism. Research interest has focused on whether this fragment may support lipolysis, the breakdown of stored fat, without the broader anabolic or diabetogenic effects associated with full growth hormone.
Fat Metabolism Signaling
AOD 9604 is commonly discussed for its potential to influence fat breakdown and fat utilization. This is the main reason it appears in weight-management and body-composition discussions.
Not the Same as Growth Hormone
AOD 9604 is not full human growth hormone. It does not provide the full range of hGH effects and should not be viewed as interchangeable with growth hormone, growth hormone secretagogues, or GHRH/GHRP combinations.
Mixed Human Evidence
Early studies suggested possible weight-loss effects, but later and larger studies did not consistently show meaningful results compared with placebo. For this reason, AOD 9604 is best described as investigational rather than proven for fat loss.
Commonly Discussed AOD 9604 Protocols
The following are commonly discussed research-use protocols and should not be interpreted as medical advice.
| Protocol Style | Commonly Discussed Amount | Frequency | Notes |
|---|---|---|---|
| Conservative Research Protocol | 250 mcg | Once daily | Often used as a lower starting point |
| Standard Research Protocol | 300-500 mcg | Once daily | Commonly discussed range |
| Higher Research Protocol | 500 mcg | Once daily | Often used in body-composition discussions |
| Split-Dose Approach | 250 mcg twice daily | Morning and later day | Less common, sometimes discussed due to short activity window |
What Users Commonly Report
| Timeline | Common Reports |
|---|---|
| Week 1 | Usually subtle effects, little noticeable change |
| Weeks 2-4 | Some users report improved body-composition momentum when paired with diet and training |
| Weeks 4-8 | Effects, if noticed, are typically gradual rather than dramatic |
| 8+ Weeks | Often evaluated based on waist measurement, scale trend, and consistency |
Potential Benefits Discussed
- Support for fat-metabolism research
- Possible lipolysis-related effects
- Interest in abdominal-fat reduction research
- Non-stimulant profile
- Often discussed alongside diet, cardio, and GLP-1 research compounds
Potential Side Effects
AOD 9604 is generally described as well tolerated in available human studies, but side effects may still occur.
Commonly discussed side effects include:
- Injection-site irritation
- Redness or tenderness
- Headache
- Mild nausea
- Water-retention-like changes in some users
- Minimal noticeable effect in some cases
Important Research Considerations
AOD 9604 should not be presented as a guaranteed fat-loss compound. The evidence is mixed, and later trials did not clearly establish it as an effective obesity treatment.
It is also important to note that AOD 9604 is prohibited by WADA and may be relevant for tested athletes.
FAQ
Is AOD 9604 the same as hGH?
No. AOD 9604 is a small synthetic fragment related to the 176-191 region of human growth hormone. It is not full growth hormone.
Is AOD 9604 used for fat loss?
It is commonly discussed in fat-loss and body-composition research, but human results are mixed. It should not be described as proven for weight loss.
When is AOD 9604 commonly taken?
It is often discussed as being used once daily, commonly in the morning, fasted, or before activity.
How long does AOD 9604 take to notice?
When effects are reported, they are usually gradual and tied closely to diet, training, and overall calorie balance.
Can AOD 9604 be stacked with other compounds?
It is often discussed alongside GLP-1 compounds, CJC-1295 no DAC, Ipamorelin, MOTS-c, or 5-Amino-1MQ, depending on the research goal.
Brief Research Summary
AOD 9604 is a synthetic growth-hormone fragment developed for fat-metabolism research. Human studies suggest it has generally been well tolerated, but its weight-loss effects have not been consistently demonstrated across clinical trials. Because of this, AOD 9604 is best positioned as an investigational peptide with interest in lipolysis and body-composition research, rather than a proven obesity or fat-loss treatment.